This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 3, 2013 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The
University of Texas MD Anderson Cancer Center to detect transrenal
BRAF mutations in the urine of patients with advanced or metastatic cancers.
Researchers will use Trovagene's proprietary transrenal DNA (TrDNA) detection technology to evaluate
BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate (RR); stable disease (SD); progression-free survival (PFS); and overall survival (OS). Results from patients who receive therapy that reflects their
BRAF mutation status (e.g., BRAF inhibitors, MEK inhibitors) will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status.
According to recent estimates,
BRAF mutations are present in more than 20% of all cancers, and in 40% and 43% of all thyroid and skin cancer samples, respectively
1. Several targeted therapies for
BRAF-mutated melanomas are already on the market and in development, including BRAF inhibitors vemurafenib (Zelboraf
®) and dabrafenib; and trametinib, a MEK inhibitor.
"One of the potential benefits of TrDNA would be its utility as a systemic, liquid biopsy, providing real-time information that may help guide targeted therapy decisions, and then help clinicians more easily monitor a patient's therapeutic response and disease state," said
Filip Janku, MD, PhD, principal investigator for the study at MD Anderson. "A urine-based assay that reliably and cost-effectively detects mutations would be extremely useful as an aid in personalized medicine."
"This study represents a first-of-its kind look at how urine-based mutation detection can be used to track patients from initial diagnosis through therapy, and then to monitor for early signs of progression," said Dr.
Charlie Rodi, chief technology officer at Trovagene. "We are pleased to sponsor this study with MD Anderson, and look forward to learning more about the unique properties and clinical utilities of our transrenal mutation assays."
1. Prevalence of BRAF mutations in various cancers. Sanger COSMIC site.
http://cancer.sanger.ac.uk/cosmic/gene/overview?ln=BRAFAbout Trovagene, Inc.
San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample. As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges associated with biopsy, as well as the volume limitations of blood.
Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myelogenous leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients, as well as other hematologic malignancies.